Biotech Values

[DewDiligence]

Buying calls makes little sense to me here. There is unlikely to be an explosive move to the upside (chances are better for a slow and steady increase over a long period)…

I’m not sure I agree that a slow and steady rise is more likely than an abrupt rise; several kinds of events could result in the latter:

1. FDA approval of generic Copaxone.

2. A partnership deal for M118.

3. A partnership deal for an FoB program.

4. A partnership deal for M402.

5. Formal FDA rejection of Teva’s Lovenox ANDA (unlikely, but possible).

6. A buyout offer at a large premium.

Because the timing of the above events is difficult to predict, I think the best approach to MNTA is to dispense with buying or selling options and to simply own the stock. However, simply being long the stock is apparently not exciting enough for some of the readers on this board. Regards, Dew